Anavex Life Sciences
$2.41
$0.05 (+2.12%)
$2.40Day Range$2.48
Key Statistics
Market Cap
$218.76M
Shares Outstanding
92.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 2, 2006
Round Lot
100
Locale
US
Trading Data
Day Open
$2.41
Day High
$2.48
Day Low
$2.40
Volume
364.8K
VWAP
$2.42
Prev Close
$2.36
Transactions
--
Acc. Volume
--
About Anavex Life Sciences
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283634 employees630 5TH AVENUE, NEW YORK, NY, 10111844-689-3939IPO Aug 2, 2006US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001314052
- Composite FIGI
- BBG000C9K8K4
- Share Class FIGI
- BBG001SLQWW6
- Ticker Root
- AVXL
- SIC Code
- 2836
About Anavex Life Sciences (AVXL) Stock
Anavex Life Sciences (AVXL) closed the 2026-09-17 session at $2.41, up 2.12% versus the previous close (+0.05). The stock opened at $2.41 and traded between $2.40 and $2.48 during that session. Session trading volume was 365K shares. The volume-weighted average price (VWAP) is $2.42.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Anavex Life Sciences has a market capitalization of $218.8 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. AVXL is listed on the XNAS exchange. The company employs approximately 34 people. Anavex Life Sciences is headquartered in NEW YORK, NY. The recorded listing date is 2006-08-02.
On this page you can find market AVXL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.